Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination with Temozolomide Versus Temozolomide Alone in Subjects with Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Temozolomide
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 08 Feb 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 13 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016, as per ClinicalTrials.gov record.
- 13 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2016, as per ClinicalTrials.gov record.